

## Index

### a

- ab initio* cell design, 234
- accelerostat, 234, 237, 240
- acetate recycling, 242
- acetyl-CoA synthetase (Acs), 242
- acoustic wave separators (AWS), 220
- active pharmaceutical ingredient (API), 564
- adaptastat, 246
- adaptive control techniques, 14
- adsorption train, 467
- advanced skills, 553
- AEX. *see* anion exchange (AEX)
- affinity chromatography, 329, 344, 417
  - process design objective, 357
- agile approach, 109
- Air Wheel bioreactor, 37
- ÄKTA Explorer 10 system, 54
- ÄKTA FPLC system, 54
- ÄKTApcc, 49, 467
- AKTA PuRe purification system, 581
- Akta purifier system, 352
- ÄKTA system, for 3C-PCC, 50
- alternating tangential filtration (ATF)
  - application of, 211
  - ATF<sup>TM</sup>-4 system, 39
  - details for different bioreactor sizes and scale-up, 211
  - filtration module, 38
  - physical bioreactor characterization, 465
  - systems, 40, 208, 210, 211, 216, 273, 463, 470, 483, 491
- amino acids, 329
  - concentration, 518
- analytical cation exchange chromatogram, 414
- analyzer calibration, 539
- ancillary systems, 525
- animal cell culture, bioprocesses, 301
- animal cell separation, hydrocyclone
  - designed, 39
- anion exchange (AEX), 572
  - chromatography, 572
  - flow-through pool, 581
  - flow-through validation, 315
  - membrane chromatography, 580
- antibody, 474
  - drug substance, 573
  - isoform separation, 412
  - manufacture, 578
  - production phase, 178
  - purification, 482
  - volumetric productivity, 36
- antibody drug conjugates (ADC), 414, 425
- Applikon BioSep system, 212
- aqueous two-phase extraction (ATPE), 271, 482
  - purification effect, 498
- aqueous two phase system (ATPS), 42, 51
  - devices, 272
  - DoE-based experiments, 497
  - separation
    - counter-current mixer-settler battery, schematic representation of, 52
- ascorbic acid, 495
- A-stat, 242, 246
  - applications, 242, 243
  - cultivation, 243
  - integration with Omics methods, 243
  - technology, 16
  - yeast physiology studies, 243
  - yields, 243
- ATF. *see* alternating tangential filtration (ATF)
- ATF2 device, 464
- automated microbioreactors, 183
- auxiliary electrodes, 139
- auxoaccelerostats, 245, 246
  - culture, 245
- auxostats, 245
- axial pumping stirrer, 141

### b

- Bachellier-impeller, 145
  - mixing profile, 146
  - prototype design, 146

- bag film materials
  - testing, 137
- basal medium screening, 183
- batch and continuous protein refolding processes, 277
- batch bioprocesses, 445
- batch chromatography, 325–327, 330, 393, 394, 399, 415
  - with linear elution gradient, 331
  - MCC, comparison of, 576
  - processes, 55, 330
  - system, 330
  - trade-offs, 399–400
  - transformation of, 335
  - true moving bed/simulated moving bed/comparison, 370
- batch downstream process, 274
- batch/fed-batch processes, 207
  - cell cultivation, 31
- batch fermentation, 405
- batch/lot, definition, 527
- batch manufacturing, 565
- batch operations, 574
  - advantages and disadvantages, 460
- batch paradigm, in synthetic drug industry, 31
- batch polishing, 418
- batch processing, 359, 538, 575
- batch purification
  - for monoclonal antibodies, 111
  - resin chromatography, 31
- batch-topped off filtration, 273
- batch UF/DF system, 582
- batch virus reduction filtration step, 316
- batch-wise processing, 468
- Bayer Technology Services, 161
- Beer–Lambert law, 385
- BEND Mast aseptic sampling system, 118
- BeneFIX, 522, 527
- binary mixture, 342
- binary separations, 329, 349
  - principle of operation, 44
- bind/elute mechanism, 331
- bioburden contamination, 551
- bioburden filtration, 112
- bioburden reduction filtration, 117
- bioburden testing, 448
- biochemical processes, steady-state flux patterns of, 233
  - environmental conditions, relationship, 233
- biochromatography, 369
- biocomparability, 355
- Bioflo 110, 37
- Biogen mAb
  - downstream platform process, 571
  - platform, 580
- biological contaminants, 289
- biologic drugs contaminations, 290
- biomanufacturing, 142, 301
- biomass
  - concentration, 245
  - constant feeding profiles, effect of, 19
  - exponential feeding profiles, effect of, 20
- biomolecules, hydrophobic characteristics of, 329
- biopharmaceutical companies, 149
- biopharmaceutical downstream process, 380
- biopharmaceutical landscape, 149
- biopharmaceutical manufacturing, 149, 397
- biopharmaceutical purification processes
  - viral clearance robustness, 55
- biopharmaceutical sector, 31, 178, 343
- bioprocess complexity, 8
- bioprocesses, 298
  - intensification, 178
- bioreactors, 172, 176, 206
  - confirmation, 191
  - data, 184
  - operating conditions, 476
  - process, 171
  - technologies for clinical/commercial scale manufacturing, 155
  - volume, 175
- BioSC<sup>®</sup>, 467
- Bioseper acoustic perfusion system, 212
- bioseparation problem, schematic illustration, 407
- BioSep device, 212
- Bioseper system applications, 212
- BioSMB system, 50, 58, 575
  - BioSMB<sup>™</sup>, 467
  - CMCC system, 124
  - protein A chromatography, 113
- biotech
  - continuous process models, 12
  - complexity, 11
  - control, 14
  - process monitoring, 13
  - iterative process development, 14
  - fed-batch technology, 16
  - methods for development, 14
- biotechnological process, 369
  - characterization, 8
  - upstream process, 33
- black box models, 12
- blank analysis, 562
- bovine serum, 291
- bovine serum albumin (BSA), 50, 344
- bovine spongiform encephalopathy (BSE), 291
- breakthrough (BT), 401
- breakthrough curve, schematic illustration, 402
- BSE. *see* bovine spongiform encephalopathy (BSE)

- BT. *see* breakthrough (BT)
- buffer compositions, 333, 357
- buffer consumption, 337, 359, 401
- buffer gradient, 338
- buffer strength, 332
- butyric acid, biphasic perfusion, 36
- c**
- CaCl<sub>2</sub>/ethanol continuous precipitation process, 53
- calcitonin, 412
- capacity utilization (CU), 401
- capillary gel electrophoresis, 474
- caprylic acid (CA), 53
- capture applications, 400–406
- examples, 405
  - process principle, 403
- capture operation, cycle length of, 469
- CaptureSMB
- configuration, 359, 360
  - process, 337
  - units, 353
- carbon dioxide mass transfer coefficient, 142
- Carman–Kozeny equation, 358
- β-carotene, in microalgae *D. tertiolecta*, 243
- carotenoids lutein, 243
- cation exchange
- chromatogram, 415
  - chromatography, 425
  - MCSGP process, 46
- caustic stability, 402
- cell banks, 291, 293
- cell cultivation processes, 5
- cell cultures, 237, 295
- based products, 4
  - broth, 177
  - Cell Culture Engineering, 31
  - contamination in, 291
  - growth, 526
  - media, 180, 293, 299, 300
  - – NaCl addition, 518
  - medium development, limitation, 180
  - steady-state of, 233
- cell cycle mechanisms, 234, 236
- cell design, 235
- cell geometry, 234, 236
- cell-less biomass, 248
- cell lines, 293
- genetic stability, 522
  - selection and testing, 290
  - specific requirements, 181
  - stability, 474
- cell lysis, 262
- cell metabolism, 235
- cell microenvironment
- various process parameters interaction, 144
- cell physiologies theories, 233, 234
- cell productivity, 462
- cell retention, 11
- ATF /TFF system for, 464
- cell retention device (CRD), 39, 171, 173, 176, 210, 213, 483
- classification, 176
  - selection of, 176
  - used for continuous upstream process, 208
- cell separation devices, 35, 38, 134
- cell settlers, 38
- cell-specific perfusion rate (CSPR), 35, 173
- CELL-tainer<sup>®</sup> bioreactor, 142
- application of, 142
  - single-use, 137, 145
- cellular behavior study, omics methods, 180
- cellular metabolism, 178
- Cellvento CHO-100 medium, 188
- Center for Drug Evaluation and Research (CDER), 514
- centrifuges, 214
- cell retention devices, used in perfusion process, 210
  - continuous disk stack, 40
  - rotor, 263
  - SEC diagram of, 497
  - semicontinuous perfusion (SCP), 187
- CEX elution peak, 315
- CFI. *see* coiled flow inverter (CFI)
- changestat methods
- advanced continuous cultivation methods, 237–242
  - categories, 240
  - – chemostat-based methods, 240
  - – turbidostat-based methods, 240
  - cultivation methods, 237
  - deceleration-stat, 244
  - experiments, 238
  - for GSA, benefits, 240
  - review of results, 242–247
  - tools for scanning steady-state growth space, 240
- charge isoform profile, product quality, 475
- CHEF1 cell line, 215
- chemical engineering, 327
- chemoenzymatic processes, 4
- chemostats, 233, 236, 237, 240
- cultivation method, 236
  - – disadvantages, 233
  - cultures, 184
  - – drawback, 233
  - – tool for SSGSA, 236
  - steady-states, 237
  - – metabolism, 236
- Chinese hamster ovary (CHO), 34, 181, 267
- based monoclonal antibody, 212

- cell lines, 185, 470
- – DHFR system, 58, 519
- – K1 cell line, 181, 189
- – lineage and development history, 182
- cells, 40
- – mAb produced, integrated perfusion/capture of, 57
- – recombinant technology, 459
- – shear stress impact, 145
- culture, gymetrics up-stream pH sensor, 140
- chiral separations, 329
- batch separations, 330
- PR&D phase, 333
- CHO. *see* Chinese hamster ovary (CHO)
- chromatogram, 331, 396, 582
- chromatographic capture process
- harming proteins, separation of, 466
- high product affinity, 466
- chromatographic columns, 461
- chromatographic interactions, 328
- types of, 326, 329
- chromatographic polishing applications, 406–414
- chromatographic technology, 268, 311, 324, 326, 369, 393, 516
- flow-through, 311
- interaction mechanisms used in, 328
- manufacturing aspects, 396–399
- multicolumn, 311
- separations, 54
- – purification processes, 326
- simulated moving bed, 311
- steps, 393
- – capture step, 393
- – flow sheet of a possible continuous process, 501
- – manufacturing constraints, 396
- – polishing steps, 393
- CIP. *see* clean-in-place (CIP)
- classical detection methods, 385
- classical single-column chromatography, 370
- classical SMB (4-SMB) and 1-SMB with 7 stirred tanks, comparison, 377
- cleanability, 355
- clean-in-place (CIP), 42, 218
- cycles, 298
- lines, 355
- regimes, 450
- skids, 573
- steps, 355
- strategy, 357
- CMOs. *see* contract manufacturing organizations (CMO's)
- Code of Federal Regulation (CFR), 555, 560
- coextruding, 137
- coiled flow inverter (CFI), 265
- based reactor, 276
- continuous precipitation, 267
- reactor (*see also* coiled flow inverter reactor (CFIR))
- use of, 55
- coiled flow inverter reactor (CFIR)
- case study, 276
- CO<sub>2</sub> incubator, 34
- column capacity, 357
- column characteristics, influence separation performance, 342
- column configurations, 348
- theoretical comparison, 359
- column length, 347
- 6-column MCSGP, 379
- column packing, 343, 355
- 3-column PCC (3C-PCC) system, 47
- columns cycle, 334
- column variability, 355
- column volume (CV), 331
- complex mixtures, 343
- computational fluid dynamic (CFD), 13, 355
- computer aided biology (CAB), 12
- computer aided process engineering (CAPE), 12
- concentrated fed-batch (CFB), 179
- processes, 175
- concentration factor (CF), 433
- connected chromatography steps, 580
- current and pool-less process, 581
- conservatism, in biopharmaceutical sector, 31
- constraint-based metabolic network models, 248
- contaminants, 488
- Contichrom® Lab-10, 467, 472
- continuous affinity chromatography, 337
- continuous annular chromatography, 394
- continuous batch chromatography, 327, 331, 358
- using multiple columns, 336
- continuous batch operation, 338
- continuous biomanufacturing process, 289, 294, 513, 550, 551
- advantages, 550
- ASTM, 521
- capital expenditure/cost reduction, 550
- defined, 549
- efficient facility/personnel utilization, 550
- EMA Guideline, 521
- FDA support, 513, 520
- ICH, 520
- implementation of, 513
- manufacturing consistency, 550
- PAT applications
- – as facilitator for implementation, 514
- – in pharmaceutical industry, 516

- process validation, 519
- quality, 551
- regulatory documents, 520
- scale-down for continuous bioprocessing, 524
- single-use equipment/components, 217
- single-use systems impact in process validation, 526
- validation, 521
- continuous bioprocessing, 150, 154, 303, 550
  - advantages of, 3
  - challenges, 5
    - in continuous biomanufacturing, 5
    - engineering approach to complex systems, 8
    - inherent changes in microbial system, 6
    - lack of process information, 7
    - models-based process development, 8
  - computer-aided operation of robotic facilities, 20
  - concerns for, 158
  - continuous downstream processing, 155
  - continuous-like fed-batch cultivations, 18
  - continuous upstream processing, 154
  - development, 3, 302
  - limited control strategies, 9
  - mimicking industrial scale conditions in lab, 17
  - model building/experimental validation, 21
  - operational issues, 158
  - platform, end-to-end, 278
  - technologies, regulatory aspects, 164
  - traditional control strategies, 9
- continuous bioproduction (CB), 218
- continuous capture development, 466
  - continuous two-column capture process, 467
  - objectives/requirements, 466
  - process control, 469
  - process performance, 468
- continuous capture step, process design of, 357
- continuous cell cultivation processes, 32
  - cell retention devices, 36
  - continuous bioprocesses, 33
    - early/scale-down perfusion development, 34
    - feeding/operational strategies in perfusion processes, 35
- continuous chromatography processes, 340, 370, 393–396, 485
  - comparison, 387
  - countercurrent multicolumn gradient chromatography, 378
  - integrated countercurrent chromatography, 379
  - risk assessment of, 353
  - serial multicolumn continuous chromatography, 377
  - SMB, 370–377
  - use in biopharmaceutical industry, 394
- Continuous cocurrent diafiltration, 273
- continuous countercurrent tangential chromatography (CCTC), 50
  - multicolumn gradient, 378
  - for protein A purification of mAbs, 51
- continuous cultivation methods, 236
  - accelerostat, 237
  - advanced, 237–242
- continuous culture, 237
- continuous diafiltration, 274, 582
  - configurations, 583
- continuous downstream process, 41, 155, 275, 573
  - batch, productivity comparison of, 585
  - continuous annular chromatography (CAC), 42
  - continuous chromatography, 157
  - continuous countercurrent tangential chromatography (CCTC), 50
  - continuous liquid chromatography (CLC), 42
  - multicolumn countercurrent solvent gradient purification (MCSGP), 45
  - periodic countercurrent chromatography (PCC), 47
  - tangential flow filtration, 156
  - true and simulated moving bed chromatography (TMB/SMB), 43
- continuous feed stream, 342
  - flow rate, 398
- continuous fermentation, 397, 419
- continuous flow UVC reactor (UVivaterc), 523
- continuous integrated process
  - bioreactor operation, 470
  - cell growth, 470
  - monoclonal antibody
    - capture, 472
    - production, 471
  - perfusion bioreactor, 460
  - process performance, 473
  - product quality, 474
- continuous liquid chromatography (CLC), 42
- continuous manufacturing, 419
  - approach, pharma companies, 551
  - framework for, 323
  - platform, 262
- continuous monoclonal antibody laboratory
  - horseshoe lay-out of, 160
- continuous multicolumn chromatography (CMCC), 124
  - conceptual diagram of, 157
- continuous operation, 328, 356
- continuous over batch manufacturing, 549
- continuous perfusion bioreactors, 191
- continuous processing (CP), 218
  - perfusion, 141, 145
  - requirements, mass transfer and mixing, 141

- continuous process verification (CPV), 447, 448
  - continuous protein refolding, 264
  - continuous quality verification (CQV), 521
  - continuous seed train, 145
  - continuous separation, of BSA and myoglobin, 352
  - continuous stirred tank reactor (CSTR), 5, 53, 265
  - continuous ternary separations, 351
  - continuous UF/DF processes, 582
  - continuous upstream processing, 154, 207
  - continuous validation, 541, 542
    - management and personnel, 544
    - of process, 533, 544
  - continuous viral inactivation, 578
    - set-up, 579
    - virus clearance processes, 54
  - contract manufacturing organizations (CMO's), 552
    - actual formulation approach, 563
    - benefits, 553
    - buildings/facilities, 555
    - capacity constraints, 553
    - change management/control, 556
    - compliance, 556
    - extractable and leachable analysis, 560, 561
    - leachables analysis, 561
    - loss of flexibility, 554
    - model approach, 562
    - quality concerns, 553
    - relationships, 553
    - risk assessment, 556
    - risks of working, 553
    - single-use technology, 555
    - supply chains, 555
    - validate to eliminate, 557
  - control charting, 540
    - choosing, 542
  - conventional batch bioprocesses, 294
  - conventional SMB process, 375
  - conveyor belt, 394
  - copper sulfate, crystallization, 267
  - corrective and preventative actions (CAPA), 557
  - Corynebacterium glutamicum*, 244
  - cost distribution, in USP/DSP, 486
  - cost issues, process validation, 543
  - cost of good (COG), 203, 209, 487
  - cost–risk assessment, 356
  - cost savings, 553
  - costs of goods (COGs), 203
  - countercurrent, 340
    - chromatographic processes, 395, 396, 399, 409
    - diafiltration, 438
    - flow, 351
    - process analogy, 395
    - single-pass diafiltration, 438
  - Crabtree effect, in yeast, 243
  - CRD. *see* cell retention device (CRD)
  - Cricetulus griseus*, 181
  - critical material attribute (CMA), 448
  - critical process parameter (CPP), 221, 327, 522, 534, 542
  - critical quality attribute (CQA), 3, 327, 490, 522, 534, 542
  - cryopreserved cells, 186
  - CSEP process, 349
    - from Carbon Calgon, 350
  - CSPR. *see* cell-specific perfusion rate (CSPR)
  - CU. *see* capacity utilization (CU)
  - cultivation vessels, 186
  - current manufacturing setup, 580
  - cycle durations, yield of capture process, 473
- d**
- DASGIP 2.5L bioreactor system, 463
  - DBC. *see* dynamic binding capacity (DBC)
  - dead-end filtration, 304
  - DEAE membrane radial column, 271
  - deceleration-stat (De-stat), 244
  - DeltaV controller, 114
  - denatured and reduced (D&R), 266
  - design batch chromatogram, 411
  - design of experiment (DOE), 17, 276, 426, 492, 521, 552
  - design qualification (DQ), 539
  - De-stat, 244
  - diafiltration, 583
  - diafiltration (DF), 572
  - dihydrofolate reductase (DHFR), 181
    - transfection system, 186
  - dilution rate stat (D-Stat), 244
  - diode array detector (DAD), 385
  - disposable, 557
  - DNA microarray-based transcriptomics, 525
  - DNA replication, 249
  - downstream (DSP), 482
    - bioprocessing production, 261
    - case study, 494
    - components
      - stainless steel and single-use, 209
    - development, 489, 491
    - in continuous mAb manufacturing, 484
    - methodical approach regarding impurity processing, 492
    - processing, 486, 551, 571, 573
    - case studies, related to continuous manufacturing, 276
      - cell lysis, 262
      - centrifugation, 263
      - chromatography, 267
      - continuous annular chromatography (CAC), 267

- continuous extraction, 271
- continuous filtration, 272
- continuous manufacturing technologies, 262
- continuous process development, 274
- countercurrent tangential (CCT), 269
- design, 41
- expanded bed chromatography (EBC), 269
- experimental presentation of the methodical approach, 493
- periodic countercurrent chromatography (PCC), 269
- precipitation, 267
- purification, 393
- refolding, 264
- schematic presentation of the methodical approach, 492
- step, 396
- scheme, 324, 325
- trends/integration approaches, 490
- unit operations, 486
- drug-antibody ratio (DAR), 414
- drug development, 311
- drug product (DP), 207, 298
- drug proteins production, 181
- drug substance (DS), 207, 572
- dry sensors, 140
- D-stat, 246
- Dunaliella tertiolecta*, 243
- dynamic binding capacity (DBC), 401
- dynamic breakthrough (DBC), 336
  - curves, 358

**e**

- Ebola virus, 33
- EcoPrime Twin, 337
  - LPLC system, 338
  - process, 354
  - 100 prototype, 325
- electrode reuse, disadvantages, 139
- electron beam irradiation ( $\beta$ -irradiation), 138
- eluent consumption, 44
- elution, 407
- EMD Millipore ProstaK™-microfiltration series, 213
- EMD Millipore's Pellicon® 3, 439
- EnBase® technology, 16
- endogenous retroviruses, 303, 306
- endogenous virus, 290
- Engage®, 138
- enzyme capture, using a HIC resin, 57
- equilibrium processes, 234
- equilibrium thermodynamics, 234
- equipment components, risk assessments of, 356

- Escherichia Coli*, 7, 33, 134, 243, 264
  - acetate overflow metabolism in, 242
- ethylene vinyl acetate, 355
- European Medicines Agency (EMA), 261
- Evatane®, 138
- exogenous/adventitious virus, 290
- expanded bed chromatography (EBA), 43
- experimental validation, 385
- extracapillary space (ECS), 219
- extractables, 153, 558
  - risk assessments, 452
- extraneous contamination, 290

**f**

- fast moving consumer good (FMCG), 261
- FBA. *see* flux balance analysis (FBA)
- FBS. *see* fetal bovine serum (FBS)
- fed-batch
  - based processes, 420
  - batch upstream production process, 206
  - bioreactors, 297
  - and continuous/perfusion upstream process, 204
  - cultivation *vs.* perfusion, 172
  - culture processes, 32
  - fermentation, 419
  - manufacturing processes, 216
  - media, 180
  - moving to integrated continuous operation, 463
  - processes, 3, 20, 172, 483
  - reactors, 459, 461
  - system, 584
  - volumetric productivity
    - *vs.* perfusion process, 143
- feedback controller, 514
- feed concentrations, 397
  - yield of capture process, 473
- feed continuity constraint, 49
- feed flow excursion experiments, 440
- fermentation
  - broths, 493
  - industrial relevant analytical methods, 488
- fetal bovine serum (FBS), 290
- fibrinopeptide, 415
- film polyethylene type materials, 137
- filtration, 38, 324
  - adsorption system, 56
  - relative yield of antibodies, 496
- five-zone continuous process for ternary separations, 351
- flat sheet cassettes, 428
- flow cytometry, 144
- flow design, 355
- flow meter, 328

- flow rates, 335, 336, 342, 348, 358
    - determination for different SMB zones, 347
  - fluorescence spectroscopy, 276
  - fluorophoric sensors, 140
  - flux balance analysis (FBA), 234
  - FMEA analysis, 345
  - FMEA, risk category, 452
  - folic acid, 495
  - Food and Drug Administration (FDA), 3, 181, 290, 534, 565
    - FDA PAT Guidance, 536
  - Fourier transform infrared spectroscopy (FTIR), 516, 562
  - fragile proteins, 171
  - fuzzy logic controls, 14
- g**
- galactosylation, 475
  - gamma irradiation, 313
  - gas chromatography with mass spectroscopy detector (GC-MS), 561, 562
  - gas dispersing impellers, 141
  - gas–liquid mass transfer, 135, 463
    - without harming cellular integrity, 470
  - GE Healthcare, 575
  - gene regulatory networks, 12
  - generic antibodies, 481
  - generic assessment, 356
  - generic integrated continuous downstream process, 324
  - generic manufacturing process, for monoclonal antibodies, 485
  - genome-scale metabolic models, 249
  - Genzyme, 159, 297
  - glutamine synthetase (GS), 181
  - glycine, 495
  - glycoforms, 461
  - N*-glycosylation, 517
  - glycosylation pattern, 517
  - GMP. *see* good manufacturing practice (GMP)
  - good manufacturing practice (GMP), 555
    - environment, 117, 461
    - GAMP5 directions, 356
    - manufacturing, 134
    - requirements, 444
  - gradient chromatography, 331, 333
  - gradient processes, 332
  - gradient SMB processes, isolation of proteins and antibodies using, 352
  - granulocyte colony stimulating factor (GCSF), 271
  - gravimetric control, of bioreactor volume, 472
  - gravimetric settlers, 172
  - gravity-based cell settlers, 483
  - growth-limiting substrate, 236
  - growth spaces, 234
    - scanning of, environmental parameter, 241
    - three-dimensional, 235
  - Gymetrics pH prototype material, 140
- h**
- Hanseniaspora guilliermondii, 243
  - HCIC systems, 271
  - HCP. *see* host cell protein (HCP)
  - heat sealers, 138
  - HIC. *see* hydrophobic interaction chromatography (HIC)
  - high-density seed bioreactors, 483
  - high molecular weight product-related species (HMW), 572
  - high performance liquid chromatography with a UV detector (HPLC-UV), 561
  - high-pressure limitations, 359
  - high-pressure liquid chromatography (HPLC), 328, 562
    - HPLC-UV, 562
    - – blank analysis, 563
    - – test extract analysis, 564
    - interference, 564
  - high-temperature short-time (HTST)
    - media exposure, 303
    - techniques, 313
    - treatment, 298
  - high-throughput (HT), 21
  - Hollow Fiber Perfusion Bioreactor (HFPPB), 219
  - hollow fibers, 426
    - media exchange, 220
    - microporous hollow fiber membranes retain, 50
    - modules, cross flow filtration, 463
    - perfusion culture, 220
  - homogenizer, high-pressure, 262
  - host cell protein (HCP), 41, 309, 393, 482, 488, 571
    - composition, 489, 493
    - concentration, 493
    - profiles, 494
    - spectrum, 482
  - HPLC. *see* high-pressure liquid chromatography (HPLC)
  - HTP methods, 498
  - HTST. *see* high-temperature short-time (HTST)
  - human-like glycosylation, 181
  - human serum proteins, 267
  - hybridoma cells, 178, 303
  - hydrocarbons, 324
  - hydrodynamic resistance
    - for the nonvolumetric centrifugal pump, 465
  - hydrodynamic stress, 180
  - hydrophilic amino acid residues, 52



- hydrophobic interaction chromatography (HIC), 227, 266, 311, 329, 344, 385, 403, 405, 412, 572
- chromatogram, 382
  - resins, 487
- i**
- 15 iCCC cycles, simulation results, 384
- iCCC process scheme, 382, 500
- ICH Q7, 527
- ICH-Q5A, 524
- ICH Q7 - Good Manufacturing Practice states, 551
- ICH Q9 - Quality Risk Management states, 551
- ICH Q10 states, 551
- IgG4 antibody, 523
- IgG capture step, 352
- IgG concentrations, 495, 497
- IgG production, 495
- Immobilized metal ion affinity chromatography (IMAC), 266
- immunological diseases, 481
- impurities, from host cells, 488
- independent qualified (IQ), 450
- in flow-through mode, 393
- information awareness, 542
- injection, 333
- innovative downstream approaches, 323
- innovative negative elution gradient, 332
- in silico ab initio* “first time right” cell design, 250
- installation and operational qualification (IQ/OQ) procedures, 134
- installation qualification (IQ), 539, 557
- insulin, 329
- integrated continuous processes, 55
- comparison of, 163
- integrated countercurrent chromatography (MCSGP), 370, 379
- basic idea of, 380
  - countercurrent behavior, 380
  - fermentation broth, 383
  - ion exchange binding capacity, 385
  - mathematical peak identification methods, 386
  - parameters for, 379
  - steps of, 383
- integrated single-use continuous bioprocessing, 159
- interaction mechanisms, 328
- interconnected operation, 337
- intermittent SMB, 374
- internal recycling, 398
- International Conference on Harmonisation (ICH), 490
- International Symposium on Continuous Manufacturing of Pharmaceuticals, 324
- in’vitro detection techniques, 291
- ion exchange, 344
- ion exchange chromatography (IEC), 266
- iSMB process scheme, 375
- isocratic batch chromatography, 372
- isocratic chromatography, 330, 332, 333
- k**
- Kalman filters, 13
- keep it simple and stupid (KISS) rule, 32
- kinetic principles, 342
- knowledge discovery of data (KDD), 12
- l**
- lab-scale systems, 353
- lack of control, 553
- lactate metabolism, 191
- Lactobacillus paracasei*, 246
- Lactococcus lactis*, 241, 243, 246
- Langmuirian-type isotherm, 342
- lauryldimethylamine N-oxide (LDAO), 571
- leachables, 559
- linear adsorption models, 348
- linear feed flow rate, 397
- linear range of Langmuir, 372
- linear retention factors, 348
- linear velocities, 336, 359, 360
- liquid chromatography (LC), 42
- liquid chromatography with a mass spectroscopy detector (LC-MS), 561
- liquid flow distribution, 397
- liquid–liquid extraction (LLE), 51, 271, 394, 482
- loading, to column capacity, 335
- load volumes, 331
- log reduction value (LRV), 293, 303, 304
- lower control limit (LCL), 541
- lower fermentation temperatures, advantage, 178
- low pH inactivation, 55
- low-pH virus, 425
- low-pressure liquid chromatography (LPLC), 328
- lysine, fermentation, 135
- lysozyme purification, 409, 410
- m**
- mAB. *see* monoclonal antibodies (mAB)
- MabSelect SuRe, 227
- protein A columns, 472
- mammalian cell culture processes, 141, 182
- mammalian cell perfusion cultures, 176, 463
- manufacturing process, 556
- marine-type impellers, 141
- mass balancing, 174
- equations, 342
- mass flow ratio, 373
- massive parallel sequencing (MSP), 291

- mass transfer, 401
  - correlations, 348
  - effects, 342
- master cell bank (MCB), 291
  - process, 356, 575, 577
- material of construction (MOC), 355, 556
- MCB. *see* master cell bank (MCB)
- MCC. *see* multicolumn chromatography (MCC)
- MCSGP. *see* multicolumn countercurrent solvent gradient purification (MCSGP)
- mechanical stress, 395
- media screening, 189
  - Cellvento CHO-100 Medium, 189
  - cultivation process illustration, 186
- membranes, 324
  - based adsorption, 482
  - fouling, 432
- Merck & Co., 160, 425
- metabolic flux analysis (MFA), 15, 234, 243
- metabolic modeling, 243
- metabolic network models, 249
- metabolic rates, determination, 174
- metabolomics, 236
- MFA. *see* metabolic flux analysis (MFA)
- M. genitalium*, 249
- microbioreactors, 15
- microchip-based circulating loop bioreactor, 15
- microfiltration processes, 179, 423
- microfluidic channel continuously, 263
- microfluidic devices, 263
- micro-Matrix (Applikon), 35
- Micro-24 MicroReactor system, 35
- microsparger, 141
- Milli-Q® water, 186
- mixed suspension and mixed product removal (MSMPR) reactors, 53, 267
- mixer-settler devices, 272
- MLV. *see* murine leukemia virus (MLV)
- mobile-phase, 342
- modeling in steady-state growth analysis, 248–250
- model solvents, 562
- model viruses, choice of, 293
- modified batch chromatography system, 351
- modular design, 353
- modular facilities, 491
- molecular mass (MM) contaminants, 51
- molecules measurement, analytical
  - methods, 236
- monitoring, for continuous processing, 536
- monoclonal antibodies (mAb), 4, 32, 34, 46, 178, 221, 301, 306, 323, 369, 401, 571
  - capture system, 56
  - DSP scheme of, 337
  - isoform separation, 413
  - molecules, 329
  - platform downstream process, 572
  - precipitation techniques, 53
  - production, 181, 289
  - for human use, 289
  - purification, 329
  - therapeutic, 304
- Monod equation, 13, 235, 236
- moving range (mR), 540
  - chart, 541
- mPES membrane, 123
- MSP. *see* massive parallel sequencing (MSP)
- multicolumn, 340
- multicolumn chromatography (MCC), 114, 405, 574, 575
  - background, 575
  - continuous capture, 575
  - continuous process, 323, 325, 398
  - technical challenges, 353
  - countercurrent chromatography, 396, 401, 414
  - continuous, 327
  - continuous upstream, 418–419
  - discovery and development applications, 414–415
  - as replacement for batch chromatography unit operations, 417–418
  - scale-up, 415–417
  - experimental results, 577
  - process optimization, 576
  - systems, 222, 224
- multicolumn countercurrent processes, 417, 418
  - regulatory aspects and control, 419–420
- multicolumn countercurrent solvent gradient purification (MCSGP), 45, 224, 270, 370, 399
  - case study, 412
  - multicolumn, 399
  - principle, 407
  - process design, 46, 340, 409
  - schematic, 411
  - with three consecutive cycles, 340
- standard process cycle of, 339
- multicolumn parallel operation, 333, 337
- multicolumn solvent gradient purification (MCSGP), 338
- multicolumn systems, 327
- multicomponent separations, 344
- multicomponent SMB system, schematic design of, 349
- Multifors 2 (Infors), 35
- multimodal chromatography, 271
  - cation exchange, 271
- multiple protein A elutions, 315
- multiple sclerosis, 481
- multivariate data analysis (MVDA), 113, 516
  - software, 127

murine leukemia virus (MLV), 303  
 murine retroviruses, 303  
 MuScan, 121

## n

N-acetyl-DL-tryptophan, 313  
 nanofiltration, for virus removal, 112  
 new mixer designs, 145  
 next-generation sequencing (NGS), 180  
 NFF. *see* normal flow filtration (NFF)  
 NIR spectroscopy, 118  
 N-linked glycosylation pattern, 475  
 non-chromatographic continuous processes, 51  
 – aqueous two-phase systems(ATPS), 51, 498  
 – DSP operation, 497  
 – – one step toward a chromatography free purification process, 500  
 – – precipitation, 499  
 – protein precipitation, 52  
 nonchromatographic steps, 418  
 nongrowth spaces, 234  
 nonideal separation conditions, 343  
 nonsteady physiological states, 234  
 nonvolatile residue (NVR), 561  
 normal flow filtration (NFF), 304  
 normalized water permeability measurements (NWP), 450  
 – measurement, 451  
 normal phase (NP), 329  
 Novartis-MIT Center for Continuous Manufacturing, 204, 261  
 N-Rich process principle, 416

## o

OCTAVE™ SMB (Tarpon) systems, 467  
 offline CEDEX cell counter measurements, 124  
 omic methods, 234, 236, 237  
 – and modeling, 243  
 on-column refolding, 265  
 – protein refolding technique, 266  
 one-cell clone, 7  
 open retention devices, 176  
 operational qualification (OQ), 539  
 operation diagram, for feed concentration, 373  
 operation qualification (OQ), 557  
 optimal chromatography process, 399  
 optimal dissolved oxygen, 141  
 optimal downstream process, decision tree, 400  
 optimal experimental design (OED), 17, 21  
 optimal operation performance, 469  
 ordinary differential equation (ODE), 13  
 organic solvents, 326  
 organized risk assessment, 556  
 OTR-limited reactors, 178  
 oxygen mass transfer coefficient, 141, 465

## p

Packed bed (PB), 219  
 packing materials, 326, 345  
 packing utilization, 325  
 parallel columns, 334  
 parallel operation, 334  
 parallel-sequential experiments, generic process, 248  
 parallel-sequential fermentation (PSF), 247  
 – scheme, 248  
 Parenteral Drug Association (PDA), 490  
 – Technical Report 26, 563  
 – Technical Report No. 66, 558  
 Parenteral Technical Report 26 (PDA TR 26, revised 2008) states, 560  
 partial least squares (PLS), 12  
 parvoviruses, 290, 306  
 PAT. *see* process analytical technology (PAT)  
 pathogen safety, 301  
 – risk mitigation, 293, 300  
 PCC. *see* periodic countercurrent chromatography (PCC)  
 PDA. *see* Parenteral Drug Association (PDA)  
 PEG400-phosphate-based ATPS, 495  
 perforated rotating disk contractor (PRDC), 272  
 performance qualification (PQ) phase, 540, 542, 557  
 perfused expansion bioreactor, 179  
 perfusion, 171  
 – advantages of, 171  
 – batch, 215  
 – bioreactors, 36, 175, 467, 470  
 – – downstream of, 58  
 – – process, 188  
 – cell culture, 11  
 – – bioreactor setup, 463  
 – – cell free harvest, 466  
 – – development, 463  
 – – objectives/requirements, 463  
 – – physical bioreactor characterization, 464  
 – comeback of, 172  
 – devices, failure, 214  
 – history, 172  
 – media, 173  
 – – development strategies, 179–184  
 – medium formulation, 179  
 – microbioreactor platform, 184  
 – processes, 34, 210  
 – – biochemical modification, 177  
 – – bioreactor temperature, 178  
 – – characterization of, 172–177  
 – – designing, 177  
 – – formats, 177–179  
 – – innovative formats, 178  
 – – limiting factors, 185  
 – – process development for, 185

- productivity, 175
- required bioreactor sizes, 178
- scale-down models, 181
- segmentation, 177
- sequential phases, 177
- steady-state definition, 176
- rate, definition, 173
- reactors, 459, 461
- scale-down applications, examples, 184
- scale-down model development, case study, 185–192
- material & methods, 186
- results, 187
- systems
  - external cell retention devices, 37
  - internal cell retention devices, 37
- periodic countercurrent chromatography (PCC), 47, 227, 274, 378, 575
  - CaptureSMB system, 49
  - cyclic operation, 270
  - schematic comparison, 47
  - system, 225
- pharma area, continuous cell culture processes, 5
- Pharmaceutical cGMP for the 21st Century – A Risk-Based Approach*, 513
- pharmaceutical industry, 327
  - single-use technologies, 150
- pharmaceutical manufacturers, 563
- pH auxostat, 10, 245
- pH sensors, 139
- physiological state of cells, 234, 237
  - environmental parameters, 234
- pillow bags, 150
- plasmid DNA, 267
- plug flow model, 377
- plug flow reactor (PFR), 5, 579
- PMMA particulate system, 466
- polishing chromatography, 399
- polyamide, 355
- polyethylene (PE), 138, 355
- polyethylene glycol (PEG), 51, 53, 271, 498
- polymeric resins, 328
- polystyrene, 355
- polysulfone, 355
- pool-less process, performance, 581
- porcine circovirus (PCV-1), 291
- porcine trypsin, virus-contaminated, 291
- posttranslational modifications, 181
- potential continuous downstream process, schematic of, 574
- PRD/GMP manufacturing environments, 355
- precipitate recovery, 53
- precipitation processes, 499
- predicted primary test method result (PPTMR), 539, 540, 543
- preparative batch chromatography, 406
- preparative continuous annular chromatography (P-CAC), 265
- pressure ratings, of chromatographic systems, 328
- pressure regulators, 355
- pressure sensors monitor, single-use, 115
- presterilized single-use wave-action bioreactors, 219
- preuse integrity test, 299
- primary test method (PTM), 539
- primary test method result (PTMR), 539
- principal component analysis (PCA), 12, 126
- probationary validation, 539
- process analytical technology (PAT), 113, 171, 222, 323, 447, 448, 515, 535, 565
  - to cell culture operations, 517
  - Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance, 565
  - implementation, 516
  - to purification operations, 518
- process development, challenges, 485
  - changing titers/impurities impact on cost structures, 485
  - host cell proteins, 488
  - impurities, as critical parameters, 487
  - regulatory aspects, 490
- process monitoring system, 534
- process performance parameters yield, simulated, 469
- Process qualification, 521
- process stream analyzers, validation/qualification of, 538
- process validation (PV), 557
  - sequence of events, 535
  - setting specifications, 535
- production rate, 358
- production record review, 555
- productivity, 336, 352, 357, 358, 360
- product life cycle management, 356
- product quality, improvement, 550
- product recalls, 290
- product-related impurities, 262
- Profibus, 114
- proof-of-concept (POC), 581
- ProSep rA (Millipore), 352
- Prostak TFF cell retention device, 213
- proteases, 482
- protein A, 358
  - adsorbent capacity
    - batch vs. MCC performance, 578
    - transport parameter, comparison, 577
  - affinity chromatography, 51, 127, 308, 425
  - based conventional technology, 53
  - CAC processes, 43
  - chromatography, 574

- ligand, 56
  - reoptimization, 577
  - protein refinery operations lab, 111
    - automation user control layouts, 116
    - biologics PAT toolkit, 119
    - case studies, 122
      - – concept automated handling of deliberate process deviations, 127
      - – continuous purification, 124
      - – perfusion, 122
    - challenges impacting biotech and biopharma industry, 110
    - CHO mAb continuous processing, 128
    - CHO mAb manufacturing improvement, 110
    - continuous mAb capture using continuous multicolumn chromatography, 125
    - design and implementation, 112
    - design and operating principles, 115
    - downstream process deviation analysis, 128
    - horseshoe layout, 114
    - mAb production, 112
    - modular facility for bioprocessing manufacturing, 111
    - multiattribute method via peptide mapping/LC-MS, 122
    - perfusion processing, 123
      - – deviation analysis, 127
    - process analytical technology (PAT), 117
      - – technologies, 118
      - – tools to support key bioprocess parameters, 120
    - real-time release (RTR), 117
      - – via PAT and parametric models, 117
    - UPSEC multiattribute process monitoring, 120
    - UV data from automated perfusion, 126
    - UV elution profiles, 125
    - viable microorganism analysis using MuScan, 121
  - Protein Refinery Operations Lab (PRO lab), 112, 113
  - proteins, 329
    - extraction of, 498
    - online peak deconvolution of, 386
    - polymerization, 249
    - refinery (*see also* protein refinery operations lab)
    - separation, 438
    - solution with refolding buffer, 265
  - proteomics, 236
  - pseudoaffinity, 405
  - pump design, 355
  - purified bovine IgG, by three-zone SMB process, 45
  - purity requirement, 342
  - purity trade-off, 407
  - push-to-low strategy, 35
  - PV. *see* process validation (PV)
- q**
- quality, 553
  - quality by design (QbD), 3, 171, 221, 426, 448, 481, 552
    - starts, 552
  - quality control, 543
  - quality management, 533
  - quantitative infectivity assays, 294
  - quantitative polymerase chain reaction (qPCR), 291
  - quasi steady-state (QSS), 248
    - parallel-sequential scheme, bioreactor system, 247
- r**
- racemic mixtures of small molecules, 329
  - racemic pharmaceutical enantiomer, 44
  - radial flow chromatography, 270
  - Raman spectroscopy, 469, 537
  - reactor design, 141
    - material aspects, 136
  - readsorption, 404
  - real time release testing (RTRT), 535
  - recombinant biologics, 301
  - recombineering methods, 234
    - CRISPR Cas9, 234
    - MAGE, 234
  - recovery/regeneration operation (REC/REG), 48
  - recycling process, 333
  - reduced cycle time, 261
  - reference electrodes, 139
  - Refine technology, 223
  - reflectance near-infrared spectrometry, 535
  - regular network models, 249
  - regulatory, 564
    - authorities, 565
    - considerations, 534
    - current regulatory references, 565
    - misconceptions, 565
    - requirements, 558
  - repeated batch (RB), 184, 187
  - residence time (RT), 185, 409
  - residual Protein A, 57
  - residual substrate concentration, 235
  - resin, 381
    - static binding capacity, 577
  - retentate pressure impact, 440
  - retrovirus-like particles (RVLP), 290, 293, 298
  - revalidations, 544
  - reverse osmosis (RO), 423
  - reverse phase (RP), 329, 344
  - reverse phase chromatography, 412
  - Reynolds number, 144, 579

- rhEnzyme proteins, 226
  - Rhodobacter capsulatus*, 244
  - risk assessment, 559
  - risk management, 552
    - of raw materials, 550
  - robust optimization program, 22
  - rocking platform-based single-use bioreactor,
    - types of, 135
  - Rogers' bell curve, 166
  - rotating circular system, prototype of CAC
    - made, 43
  - rotavirus vaccine
    - contamination, 291
    - live attenuated, 291
  - RP-HPLC, with UV detection, 563
  - RS-232 interface, 114
  - Rushton turbine impeller, 464
  - RVLP. *see* retrovirus-like particles (RVLP)
- s**
- Saccharomyces cerevisiae*, 7, 243, 244, 246
  - Saccharomyces uvarum*, 245
  - sanitization agent, validating methods, 450
  - sanitization step, 449
  - SBC. *see* static binding capacity (SBC)
  - scale-down model, 524
    - comparison, 188
    - cultivation methods, 182
    - metabolic behavior, 191
  - Scale-up and Post- Approval Change (SUPAC), 534
  - Scale-Up Aspects, 142
  - scaling-up parameters, 143
    - critical process parameters variation, 143
  - SEC. *see* size-exclusion chromatography (SEC)
  - segment-wise sterilization, 15
  - Semba Octave Chromatography System, 269
  - semicontinuous batch chromatography, 331
  - semicontinuous chemostat (SCC), 184, 187
    - mode, 187
  - semicontinuous cultivation, 183
  - semicontinuous perfusion
    - VCD, CSPR, and  $q_{IG}$ , 189
    - VCD, viability, and  $q_{IG}$ , 190
  - semicontinuous perfusion (SCP), 184, 187
    - bioreactor confirmation, 192
  - sensors, 139, 444
    - storage, condition, 140
  - sequence-based polymer composition data, 249
  - sequential multicolumn chromatography (SMCC), 378, 575
  - serial column setup, example for, 378
  - serial multicolumn continuous chromatography, 377
  - settling, 38
  - shake flasks, 184
  - shear sensitive cells, 146
  - silver-stained SDS-PAGE analysis, 57
  - SIMCA batch, 118
  - simulated moving bed (SMB), 44, 265, 295, 327, 369, 370, 395, 575
    - advantages, 372
    - approach, 296
    - binary SMB system
      - with buffer gradient, 346
      - chromatography using step gradients, 347
    - bind and elute cation exchange chromatography, 297
    - chromatography, 268, 297, 324, 329, 341, 352
    - in column concentration profiles, 371
    - column dimensions, 372
    - column height and switch time, 371
    - eight-column four-zone, 395
    - examples of, 374
    - Henry coefficient, 372
    - linear velocity of the solid phase, 371
    - modification, 352
    - parameters for, 372
    - purifications, 349
    - raffinate stream, 374
    - semicontinuous SMB-like unit operation, 375
    - separation factors, 372
    - separation zones, 371
    - 1-SMB process, zones of, 376
    - systems, 345
    - tandem SMB configurations, 345
    - tandem SMB for SEC purification of insulin, 346
    - technology, 324, 341, 345, 352
      - for biomolecules, 343
    - Varicol-SMB switching times, schematic visualization of, 374
    - velocities of zones, 372
    - zones for ternary separations, 344
  - single cell model (SCM), 234, 249
  - single column, 331
    - batch chromatogram, 409
    - batch process, 327, 359, 398, 399
    - chromatography, 393, 402
    - recycling schemes, 333
  - single-pass tangential flow filtration (SPTFF), 156, 273, 297, 423, 424, 428, 430, 572
    - application, 442
    - biopharmaceutical industry, 424
    - concentration using batch, 431
    - continuous mAb template, 429
    - continuous processing, 425
    - conversion dependency on retentate pressure, 435
    - conversion vs. concentration, 434, 435
    - conversion vs. feed flow, 440
    - graph, 436, 441

- experimental setup, 439
- feed channel, 432
- multilevel sections configuration, 443
- multiple sections, 443
- process, 431
- single holder configuration, 443
- single section configuration, 443
- single-section installations, 442
- sizing example, 442
- system, 298
- system setup, 430, 583
- ultrafiltration, 437
- unit installation, 444
- single-use (SU), 216
  - bags, 136
  - manufacturing materials, 137
  - production and assembly of, 138
  - bioreactor (*see* single use bioreactor)
  - continuous bioprocessing, adoption rate of, 165
  - disposable technology, 297
  - downstream processing, 151
    - chromatography steps, 152
    - tangential flow filtration, 151
  - equipment, 58
  - vs. stainless steel equipment, 134
  - market, 554
  - reactor types, 135
  - solutions, 554
  - systems, 149
  - technologies, 150, 172, 484, 558
    - current trends and future predictions, 153
    - early skepticism, 152
    - history of, 150
    - single-use downstream processing, 151
    - single-use upstream processing, 151
  - upstream processing, 151
- single use bioreactor (SUB), 133, 136, 216
  - classification, 135
  - overview of, 137
  - parts, 133
  - scale-up aspects, 142
  - shear effects, 144
- size-exclusion chromatography (SEC), 44, 266, 329
  - diagram, top and bottom phase, 497
  - SMB system, for insulin purification, 345
- SMB. *see* simulated moving bed (SMB)
- solid-state fermentation processes, 6
- solvent compositions, 345
- solvent consumption, 332, 343
- space time yield (STY), 175
- spectroscopy techniques, 516
- spiking techniques, 295
  - inline spiking, 295
- spin-filter technology, 40, 172, 210
- SpinTubes, 184
  - bioreactors, 184, 186
  - semicontinuous perfusion, 188
  - using, advantage, 34
- spiral wounds, 426
- SPTFF. *see* single-pass tangential flow filtration (SPTFF)
- SSGSA. *see* steady-state growth space analysis (SSGSA)
- stack injection, 332
- stainless steel technologies, 557
- standard feedback control methods, 11
- standard operating procedure (SOP), 555
- starting cell density, 188
  - determination, 187
- state-of-the-art foci, 493
- static binding capacity (SBC), 401
- statistical process control (SPC), 541
- steady-state cell physiology, 240
- steady-state cultivation methods, 234
- steady-state growth space analysis (SSGSA), 233
  - chemostat culture as tool for, 236
  - comprehensive quantitative, challenges, 236
  - high-resolution, 241
  - physiological state of cells, 234
- steady-state GSA, using parallel-sequential cultivations, 247
- steady-state metabolism, 233, 240
  - of cells, 236
  - chemostat cultivation, disadvantages, 233
  - intracellular, modeling methods, 234
  - flux balance analysis (FBA), 234
  - metabolic flux analysis (MFA), 234
- steady-state recycling (SSR), 333
  - process, flow diagram of, 334
- steady-states of metabolism, 236
- steel casting, 3
- sterile filtration, 425
- sterile tube-welder, 138
- sterilization processes, 535
- stirred bioreactors, 34
- stirred tank bioreactor (STR), 34, 219
- stirred tank perfusion bioreactor setup, 464
- straight-through processes (STP), 53, 54, 581
- Streptococcus thermophilus*, 246
- SUB. *see* single use bioreactor (SUB)
- substitute solutions, use of, 561
- surface-enhanced Raman scattering (SERS), 516
- switches
  - pairs of tasks, 408
  - time, 335
- synthetic peptides, 329
- system behavior analysis, 9
- system control method, 9
- system design method, 9

**t**

- tandem configurations, 344
  - tangential flow filter (TFF), 40, 151, 156, 424, 426, 463, 464
    - advantages, 429
    - applications, 424
    - batch
      - fed-batch, 433
      - vs. single-pass, 426
    - cell retention device, 213, 470
    - disadvantages, 429
    - equipment configuration/requirements, 442
    - flux excursion batch, 433
    - laboratory-scale process development example, 438
    - membrane type and format for applications, 426
    - modes of operation, 427
    - physical bioreactor characterization, 465
    - pressure-independent region, 436
    - process design, 430
    - Prostat system, 213
    - schematic drawing, 37
    - serial and parallel configuration, 431
    - single-pass tangential flow filtration (SPTFF), 428
    - systems, 470
    - UF holder, 442
  - Tarpon Biosystems BioSMB, 269
  - ternary separations, 344
  - TFF. *see* tangential flow filter (TFF)
  - therapeutic oligonucleotides, purification, 352
  - therapeutic proteins, 109
  - thermodynamics, 234, 342
  - thermoplastic elastomers, 138
  - three-column capture process (3C-PCC), 47
    - breakthrough curve, 48
    - protein A columns of, 55
  - TMP. *see* transmembrane pressure (TMP)
  - TOC flush residuals, 450
  - total organic carbon (TOC), 561
  - traditional batch processes, 294, 296
  - traditional batch processing, 295
  - traditional steel or glass bioreactors, 134
  - transcription-mediated amplification (TMA), 291
  - transcriptome analysis, 180
  - transcriptomics, 180, 236
  - transit time, 397
  - transmembrane pressure (TMP)
    - feed channel, 432
    - filtrate flux dependency, 432
  - transmissible spongiform encephalopathies (TSE), 289, 300
  - triangle theory, 342, 347, 352
  - tri-*n*-Butyl phosphate (TnBP), 310
  - Triton X-100, 310
  - true moving bed (TMB), 44, 341, 371, 395
    - chromatography, 43
  - TSE. *see* transmissible spongiform encephalopathies (TSE)
  - tubing, proper guiding, 136
  - Tunable Aqueous Polymer Phase Impregnated Resins (TAPPIR®), 52
  - turbidostat, 9, 245
  - twin-column CaptureSMB process, schematic illustration, 403
  - twin-column countercurrent processes, 400
  - twin-column MCSGP process principle, schematic illustration, 408
  - twin-column process, 337, 355, 398
    - capture process, flow chart of, 468
  - two one-sided test (TOST), 525
  - two-phase liquid extraction, 369
  - Tygon tubing, 277
- u**
- ultrafiltration (UF), 423, 572
    - cassette modules, 439
    - DF systems, 572
    - membrane, 438
      - configuration, 428
      - processes, 423
  - ultrasonic separators, 220
  - ultraviolet
    - detectors, 330, 444
    - elution profiles, 125
    - irradiation, 55
    - signal, 48
    - vis spectroscopy, 276
  - ultraviolet-C (UV-C)
    - gamma irradiation exposure, 303
    - radiation, 312
    - viral inactivation devices, 312
  - United States Pharmacopoeia (USP), 538
  - UPLC tools, 118
  - upper control limit (UCL), 541
  - upstream continuous/perfusion process, 207
    - acoustic wave separation, 220
    - alternating tangential filtration
      - application of, 211
      - details for different bioreactor sizes and scale-up, 211
      - system, 210, 211
    - batch and fed-batch processes, 222
    - case study-perfusion using ATF cell retention device, 212
    - cell line stability, 215
    - cell retention devices, 210
    - continuous downstream processing, 223
    - continuous flow centrifugation, 220



- costs and benefits of continuous manufacturing, 222
  - costs of adoption, 223
  - current biotherapeutics, 217
  - design objective for integrated continuous processing, 226
  - FDA supports continuous processing, 221
  - fixed/floating filter bioreactors, 219
  - hollow fiber media exchange, 220
  - hollow fiber perfusion bioreactors, 219
  - integrated continuous manufacturing, 224
  - manufacturing scale-up challenges, 214
  - packed bed bioreactors, 219
  - process complexity and control, 214
  - single-use accessories supporting perfusion culture, 220
  - single-use bioreactors for perfusion culture, 219
  - single-use continuous bioproduction, 218
  - single-use perfusion bioreactors, 219
  - single-use technologies, 215
  - spin filters, 210, 220
  - Stainless Steel and Single-Use, 209
  - stirred tank suspension reactors, 219
  - SUBs application in continuous processing, 218
  - traditional fed-batch, traditional perfusion culture, 225
  - upstream process-type selection, 209
  - validation, 215
  - upstream process (USP), 203, 481, 489
    - application, sensor for, 139
    - biomanufacturing, 205
    - bioprocessing, 302
    - case study, 494
    - continuous or perfusion, 208
    - development, 492
      - in continuous manufacturing, 483
    - experimental presentation of methodical approach, 493
    - methodical approach regarding impurity processing, 492
    - operating modes, 206
      - continuous/perfusion process, 207
      - continuous upstream/perfusion, advantage of, 207
      - fed-batch process, 206
    - optimization, 482
    - trends/integration approaches, 490
- v**
- vaccines, 109
  - validated states, verification of, 536
  - validation, of bioprocess, 355
    - between batch and continuous processing, 445
      - single-pass TFF, 449
      - virus injection, 318
  - valve configurations, 355
  - Varicol process, 375
  - Varicol-SMB switching times, schematic visualization of, 374
  - VCD time course, illustration of, 183
  - velocity, 342
  - viable cell density
    - productivity, media consumption, buffer consumption, and overall yield, 473
    - steady-state operation, 471
  - viral clearance, 54, 293, 294, 304, 311
    - validation, 299
  - viral contamination, 289
    - of biotechnology products, 290
    - sources, 293
  - viral filters, 307
  - viral genome, 290, 292
  - viral inactivation (VI), 310, 522, 578
    - chemical, 310
    - low pH, 523
    - methods, 292
    - reduction, 293
      - mechanism of action, 293
  - viral reduction
    - filters, 306, 307
    - filtration, 305, 306, 308
    - inactivation, orthogonal, 304
  - viral safety, 290, 292–294, 296
    - batch vs. continuous, 297
    - of biologics, 289
      - chemical inactivation, 308, 315
      - in continuous processing, 310
      - chromatography, 311
      - continuous processing, 295
      - downstream virus removal strategies, 304
      - gamma irradiation, 313
      - heat treatment/pasteurization, 313
      - inactivation by ultraviolet radiation (UV-C), 312
      - in-line virus injection validation method, 317
      - intermediate and polishing chromatography, 315
      - limitations, 292
      - low-pH inactivation, 308
      - of medicinal product, 292
      - normal flow filtration (NFF), 304
      - pH/S/D viral inactivation manufacturing set-up for batch manufacturing, 309
      - protein a capture chromatography, 314
      - raw material safety/testing, 299
      - risk mitigation strategies, 300
      - solvent detergent (S/D) inactivation, 310
      - typical batch vs. fed-batch vs. continuous processing modes of operation, 302

- upstream and bioreactor safety, 301
  - validation in continuous manufacturing processes, 313
  - viral reduction and inactivation unit operations, 304
  - virus filtration
    - flow decay vs. mass throughput, 318
    - manifold for continuous processing, 308
    - reduction, 316
  - viral transmission, 290
  - viral validation, 293
  - viruses
    - barrier filtration, 298, 303
    - barrier technologies, 291, 301
    - classification, 290
    - endogenous virus, 290
    - exogenous/adventitious virus, 290
    - clearance, 301
    - contamination, 290, 293, 298
    - detection methods, 291
      - analytical methods, 292
      - *in vitro* detection techniques, 291
      - quantitative polymerase chain reaction (qPCR), 291
      - transcription-mediated amplification (TMA), 291
    - filtration, 299, 306, 307, 425
    - log reduction value, 316
  - virus filters, 307, 317
    - integrity test, 299
    - log reduction value, 307
    - maximum operating pressure, 442
    - postuse integrity status, 307
    - validation, 307
  - virus inactivation, 309, 459
    - solvent detergent (S/D) treatment for, 310
  - virus reduction methods, 298, 301
    - filters, 299
    - filtration, 305
    - buffer compatibility, 305
    - facility fit, 305
    - incoming raw materials, 305
    - protein concentration, 305
  - virus removal, 301
    - efficacy, 301
    - mechanism of action
      - adsorption, 293
      - chemical inactivation, 293
      - size exclusion, 293
    - steps, 55
    - validation studies, 293, 294
      - model virus, 293
      - using scale-down models, 293
  - virus retention, 305
  - virus safety, 295, 296
    - risk mitigation, 302
    - risk reduction, 303
      - in continuous upstream bioprocessing, 303
    - risk strategies, 303
    - strategy in continuous processing, 313
  - virus spiking, 295
  - virus validation, 314
  - vitamins C and E, 243
  - volumetric concentration factor (VCF), 430
  - volumetric flow rates, 463
  - volumetric productivity (VP), 175
  - vortex flow filters, 208, 483
- W**
- waste treatment, 486
  - wave bioreactor, 35, 135, 151
  - weak cation exchange chromatography, 474
  - whole-cell models, 249
- Y**
- Yarrowia lipolytica*, 245
  - yield/purity chart, 413
- Z**
- Zika, 33